OBJECTIVES Acromegaly is a chronic and debilitating disease, which can lead to significant increases in healthcare costs. The objective of the present study was to undertake an economic evaluation of Lanreotide Autogel compared with Octreotide LAR in the management of acromegaly in the Greek health care setting. METHODS A cost minimization model was developed for the analysis which only considers the costs of treatment, as the two drugs have equal efficacy. The time horizon was 30 years; future costs were discounted at 3.5%. In addition, a budget impact analysis was conducted, with a time horizon of 5 years. The perspective for both analyses was that of Social Insurance. Data on resource use (administration setting, drug wastage and time required for the administration of each drug), as well as lab and imaging tests, were collected with the Delphi technique via an expert panel with 11 experienced endocrinologists, from University and Public Hospital specialized units. Local unit cost data were collected from officially published sources (Ministry of Health and Social Insurance Funds). One way sensitivity analyses were performed to test the results. RESULTS Lanreotide Autogel reduced total costs of acromegaly treatment by €29,896 per patient over the 30-year time horizon. 93% of the savings were attributed to the reduction in drug acquisition and administration costs. Discount rate was the most influential parameter in the sensitivity analysis. The total cost of managing acromegaly in Greece, including lab and imaging tests, over a 5-year time horizon was estimated to range between €22.9 and €22.2 million, with a 30% and 60% market share for Lanreotide Autogel, respectively. Therefore, doubling Lanreotide Autogel’s share would lead to total savings of €781,604. CONCLUSIONS Lanreotide Autogel in comparison with Octreotide LAR may result in a reduction of the total cost in the management of acromegaly in Greece.